Vaccine最新文献

{"title":"Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines","authors":"William P. Hausdorff ,&nbsp;Marco Cavaleri ,&nbsp;Marion F. Gruber ,&nbsp;Kwasi A. Nyarko ,&nbsp;Andrew J. Pollard ,&nbsp;Mateusz Hasso-Agopsowicz ,&nbsp;Julie Joseph ,&nbsp;Rakesh Aggarwal ,&nbsp;Ernest Agyei-Kwame ,&nbsp;Peter M. Dull ,&nbsp;Pieter Neels ,&nbsp;Hugues H. Bogaerts ,&nbsp;Christopher J. Gill ,&nbsp;Nancy Salts ,&nbsp;Wenxi Tang ,&nbsp;Birgitte K. Giersing","doi":"10.1016/j.vaccine.2026.128257","DOIUrl":"10.1016/j.vaccine.2026.128257","url":null,"abstract":"<div><div>Combination vaccine formulations contain distinct components targeting multiple strains of a single pathogen or multiple pathogens. By minimizing the number of separate vaccine administrations required, combination vaccines have been critical in allowing the broad expansion of the number and range of diseases that can now be prevented by immunization. Recent advances in vaccine development and our understanding of the immune system now make it possible to envision how new combination vaccines could play a major role in helping immunization programs address a much wider range of emerging or still problematic pathogens. However, few combinations are currently in the pipeline, in part due to their inherently increased complexity and cost of development compared to standalone formulations. This complexity, in turn, is partly driven by the regulatory requirements surrounding the clinical study program for the combination vaccine, especially the primary clinical endpoints and the required degree of precision around those endpoints, as these ultimately determine the sample size, cost, and duration of the study. As part of a larger effort to facilitate combination vaccine development, vaccine experts at the World Health Organization and PATH coordinated a one-day meeting in March 2025 gathering current and former national regulatory agency staff from a dozen countries, together with vaccine developers, representatives from funding and procurement agencies, and public health and policy officials. The convened participants held spirited discussions on how multiple immune markers and controlled human infection models (CHIM) might contribute to the demonstration of vaccine efficacy. In addition, participants considered the possibility of relying on clinical endpoints when the vaccine components are directed against pathogens causing the same disease syndrome but etiological determination of each component's contribution is not feasible. Regulators welcomed scientifically sound, creative proposals for demonstration of efficacy, and agreed that the benefit-risk of the combination vaccine as a whole should be the primary focus.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128257"},"PeriodicalIF":4.5,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of HPV single-dose vaccination in expanding access in GAVI-supported countries during a period of supply constraints","authors":"Robyn Stuart ,&nbsp;Nicolas Theopold ,&nbsp;Naomi Miall ,&nbsp;Emily Kobayashi ,&nbsp;Sara Vernam ,&nbsp;Tanjila Taskin ,&nbsp;Peter M. Dull","doi":"10.1016/j.vaccine.2025.128187","DOIUrl":"10.1016/j.vaccine.2025.128187","url":null,"abstract":"<div><h3>Background</h3><div>Over 2023 and 2024, 19 of the countries that were supported by Gavi to purchase HPV vaccines adopted a single-dose HPV vaccination schedule. The goal of this study is to estimate the impact on vaccination access and the number of cervical cancers averted compared to a two-dose schedule.</div></div><div><h3>Methods</h3><div>We estimated the population that could be targeted in countries supported by Gavi to purchase HPV vaccines. We used UNICEF shipment plans to identify the number of HPV doses shipped to each country in 2023 and 2024, plus information supplied by Gavi on the dose schedule implemented in each country and year, adjusting for vaccine wastage. We computed the number of girls that could have been reached, first assuming complete utilization of all shipped doses under a single-dose schedule, and second assuming a counterfactual scenario where all countries would have used a 2-dose schedule. We then compared this to country-reported data on the number of girls actually vaccinated. For each of the three scenarios we modeled the number of cervical cancers averted using HPVsim, a microsimulation model calibrated to each country.</div></div><div><h3>Findings</h3><div>We calculate that the introduction of single-dose HPV vaccination in Gavi-supported countries would have allowed these countries to target 23.3M additional girls if all supply was utilized. Reported data on girls vaccinated indicates that in actuality an additional 18.5M girls were reached due to adoption of single-dose. We estimate that the use of single-dose schedule in 2023 and 2024 could have averted up to 370,000 (356,000–376,000) additional future cervical cancers if all supply had been utilized, and 297,000 (222,000–369,000) given actual utilization.</div></div><div><h3>Interpretation</h3><div>The single-dose HPV vaccination strategy has had a substantial positive impact on cervical cancer elimination in context of supply constraints affecting low and middle-income countries.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128187"},"PeriodicalIF":4.5,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to national vaccination guidelines among pediatric cancer patients: a retrospective study from two tertiary care centers in Switzerland","authors":"Florence Anne Barbey ,&nbsp;Maria Otth ,&nbsp;Sabine Kroiss ,&nbsp;Daniel Drozdov ,&nbsp;Christoph Berger","doi":"10.1016/j.vaccine.2026.128265","DOIUrl":"10.1016/j.vaccine.2026.128265","url":null,"abstract":"<div><h3>Background</h3><div>Childhood cancer diagnosis and treatment cause significant immunosuppression, increasing vulnerability to vaccine-preventable diseases and disrupting routine vaccination schedules. In Switzerland, vaccination guidelines to support physicians caring for these patients were published in 2022. Adherence to these recommendations among pediatric cancer patients remains unknown.</div></div><div><h3>Methods</h3><div>We conducted a retrospective chart review of pediatric cancer patients (0–16 years at diagnosis) treated at two Swiss tertiary care centers between June 2022 and November 2024. Vaccine uptake was assessed at diagnosis, during, and after treatment using descriptive analyses. Exploratory analyses evaluated risk factors for under-vaccination, and occurrence of vaccine-preventable diseases was documented.</div></div><div><h3>Results</h3><div>Among 105 participants (median age at diagnosis 7.6 years [IQR 2.7–12.9]), uptake of vaccines recommended during treatment was low (pneumococcal conjugate vaccine 5%, influenza vaccine 10%, COVID-19 vaccine 19%). Post-treatment vaccine uptake was delayed and insufficient, ranging from 0 to 41% within 0–3 months following recommendation date and from 15 to 76% thereafter, depending on the vaccine. Younger age at diagnosis was associated with complete post-treatment vaccine uptake (<em>p</em> = 0.03). Vaccine-preventable diseases, including COVID-19, influenza, varicella, herpes zoster, and pertussis, occurred in 30/105 participants (29%). Most vaccines during (82%), and all vaccines after treatment (100%), were administered in primary care.</div></div><div><h3>Conclusion</h3><div>In a setting where post-treatment vaccination relies exclusively on primary care and no structured in-hospital measures are set in place, vaccine uptake among pediatric cancer patients remained insufficient. Targeted strategies are needed to improve guidelines adherence and reduce the burden of vaccine-preventable diseases, particularly among older children.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128265"},"PeriodicalIF":4.5,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of rabies immunoglobulins and monoclonal antibodies infiltrated into animal bite wounds after dilution: Real-world evidence from an anti-rabies clinic in India","authors":"D.H. Ashwath Narayana ,&nbsp;M.K. Poornima ,&nbsp;C.M. Chiranthan ,&nbsp;H.S. Ravish ,&nbsp;Reeta S. Mani ,&nbsp;Shrikrishna Isloor ,&nbsp;R. Sharada ,&nbsp;M.K. Sudarshan","doi":"10.1016/j.vaccine.2026.128233","DOIUrl":"10.1016/j.vaccine.2026.128233","url":null,"abstract":"<div><h3>Background</h3><div>WHO recommends infiltration of category III bite wounds, and category II wounds in immunocompromised individuals, with rabies immunoglobulins (RIG) to neutralize the virus at the site of exposure. Dilution with sterile normal saline is advised to ensure adequate wound infiltration. However, data on the extent of dilution across various RIGs and rabies monoclonal antibodies (RmAbs), and their effectiveness are lacking. This study aimed to generate evidence on dilution practices and outcomes following full-dose infiltration.</div></div><div><h3>Objectives</h3><div>To review the dilution ratios of RIGs and RmAbs used for full-dose wound infiltration in routine practice, and assess the clinical outcomes of the exposed individuals.</div></div><div><h3>Methods</h3><div>A desk review was conducted on 223 animal bite cases managed at an Anti-Rabies Clinic, Bengaluru, India from January 2022 to December 2024. All animal bite victims received full-dose RIG or RmAb, diluted with normal saline as required for complete wound infiltration. Survival status was verified through telephonic follow-up.</div></div><div><h3>Results</h3><div>Of the 223 cases, 133 (60%) were males, 210 (94%) cases had dog bites, 71 (31.8%) had bite from suspect rabid animals.Among 210 cases who had dog bites, 65 (31%) were attributed to suspect rabid dogs. Dilution ratios reached up to 1:1 for HRIG, 1:5.4 for ERIG, 1:20.7 for Rabishield, and 1:8.2 for Twinrab. Special groups included one pregnant woman (Twinrab) and one woman on antiretroviral therapy (Rabishield). Survival was 100%, with no rabies cases observed during 6–42 months of follow-up.</div></div><div><h3>Conclusion</h3><div>Diluted RIGs and RmAbs were found to be effective in preventing rabies when used for adequate infiltration of multiple and severe animal bite wounds, supporting the feasibility and safety of dilution practices in real-world clinical settings.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128233"},"PeriodicalIF":4.5,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults","authors":"G. Tembo ,&nbsp;D. Hoving ,&nbsp;A.C. de Kroon ,&nbsp;L. Chimgoneko ,&nbsp;T. Nthandira ,&nbsp;B. Galafa ,&nbsp;F. Thole ,&nbsp;E. Nsomba ,&nbsp;D. Dula ,&nbsp;C. Ngoliwa ,&nbsp;N. Toto ,&nbsp;L. Makhaza ,&nbsp;A. Muyaya ,&nbsp;E. Kudowa ,&nbsp;A.E. Chirwa ,&nbsp;M.Y.R. Henrion ,&nbsp;T. Chikaonda ,&nbsp;B.C. Urban ,&nbsp;D.M. Ferreira ,&nbsp;K.C. Jambo ,&nbsp;S.B. Gordon","doi":"10.1016/j.vaccine.2026.128269","DOIUrl":"10.1016/j.vaccine.2026.128269","url":null,"abstract":"<div><div>Pneumococcal conjugate vaccine (PCV13) introduction has reduced vaccine-type carriage and disease; however pneumococcal carriage persists at high rates particularly in high-transmission settings. Serotype 3 remains a particular problem in Malawi and globally, with high carriage rates, as well as strain resistance to antibiotics and antibody-mediated killing. We studied antibody and B cell responses to PCV13 in 65 healthy Malawian adults (18–40 years) taking part in a randomized controlled trial. Serum, nasal fluid, and PBMC samples were collected before and after vaccination. Anti-capsular IgG for serotypes 3 and 6B were measured by ELISA, and capsule-specific B cells were assessed by spectral flow cytometry. PCV13 increased both serum and mucosal IgG levels, and IgG⁺ B cells in blood for serotype 6B but not serotype 3. The poor immunogenicity of serotype 3 capsular polysaccharide in Malawian young adults highlights the need for alternative vaccines to address persistent serotype 3 carriage and disease.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128269"},"PeriodicalIF":4.5,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Absenteeism related to respiratory infections among healthcare personnel in hospitals in Greece from 2020–2021 to 2024–2025","authors":"Helena C. Maltezou ,&nbsp;Theodoros V. Giannouchos ,&nbsp;Maria N. Gamaletsou ,&nbsp;Dimitra-Maria Koukou ,&nbsp;Nikolaos Lemonakis ,&nbsp;Flora Sourri ,&nbsp;Emmanuela Peskelidou ,&nbsp;Evanthia Botsa ,&nbsp;Athanasia Lourida ,&nbsp;Dimitrios Hatzigeorgiou ,&nbsp;Periklis Panagopoulos ,&nbsp;Nikolaos V. Sipsas","doi":"10.1016/j.vaccine.2026.128264","DOIUrl":"10.1016/j.vaccine.2026.128264","url":null,"abstract":"<div><h3>Aim</h3><div>To study absenteeism among healthcare personnel (HCP) in Greek hospitals from 2020–2021 to 2024–2025.</div></div><div><h3>Methods</h3><div>Data were collected prospectively. Multivariable regressions were applied to estimate associations between variables, duration and cause of absenteeism.</div></div><div><h3>Results</h3><div>We studied 5525 absenteeism episodes with 38,482 days missed (17.8 episodes per 100 HCP; mean duration of absence per episode: 7.0 days). Compared to other seasons, the 2021–2022 season had the highest number of absenteeism episodes per 100 HCP (28.7) and the longest mean weekly duration of absence per 100 HCP (10.6 days per week) (<em>p</em>-value &lt;0.001 for both). Causes of absenteeism were coronavirus disease 2019 (COVID-19) (61.8%), asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (10.4%), exposure to COVID-19 (8.3%), and influenza (5.2%). The incidence of COVID-19-related absenteeism declined overtime, while influenza-related absenteeism increased gradually. Compared to unvaccinated HCP, fully and partially COVID-19 vaccinated HCP had 2.58 and 2.08 fewer days of absence, and lower odds of COVID-19-associated absenteeism [adjusted odds ratio (aOR): 0.36; 95% confidence intervals (CI): 0.26–0.51 and aOR: 0.47; 95% CI: 0.33–0.67, respectively]. The full COVID-19 vaccine effectiveness (VE) against absenteeism was 67.9% (95% CI: 64.0%–71.3%) and against COVID-19-related absenteeism was 55.8% (95% CI: 48.9%–61.8%). Influenza VE against influenza-related absenteeism was 44.8% (95% CI: 22.8%–60.6%).</div></div><div><h3>Conclusions</h3><div>COVID-19 was the main driver of absenteeism among HCP, however a gradual shift to influenza-related absenteeism occurred overtime. COVID-19 vaccination conferred protection against any absenteeism and against COVID-19-related absenteeism. Influenza vaccination significantly protected against influenza-related absenteeism. HCP should remain up-to-date with COVID-19 and influenza vaccinations to confer protection which can further safeguard healthcare facilities from absenteeism.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128264"},"PeriodicalIF":4.5,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146025051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine","authors":"Awadalkareem Adam ,&nbsp;Christy Lee ,&nbsp;Madison C. Jones ,&nbsp;Brinley R. Harrington ,&nbsp;Jing Zou ,&nbsp;Bi-Hung Peng ,&nbsp;Xuping Xie ,&nbsp;Pengfei Wang ,&nbsp;Tian Wang","doi":"10.1016/j.vaccine.2026.128255","DOIUrl":"10.1016/j.vaccine.2026.128255","url":null,"abstract":"<div><div>QS-21, a key component of several licensed vaccines is facing limited supply, dose-limiting toxicity and other drawbacks which together limit its broader usage. Development of saponin alternatives to QS-21 that retain its desirable adjuvant activity without its drawbacks is in high need. Incorporating an amide side chain into the more sustainable <em>Momordica</em> saponins (MS) I and II led to the recent discovery of two semisynthetic immunostimulatory adjuvants VSA-1 and VSA-2. Here, we showed that SARS-CoV-2 receptor-binding protein (RBD) adjuvanted with VSA-2 induced high titers of SARS-CoV-2 specific humoral and T helper-1 prone immune responses in mice comparable to that triggered by QS-21-RBD vaccination. Vaccination with VSA-2-RBD provided strong protection against SARS-CoV-2 and variants infection and the virus-induced lung inflammation and pathology similarly as QS-21-RBD vaccination. Overall, our results suggest that VSA-2 adjuvant can potentially complement the clinically proven saponin adjuvant QS-21 in vaccines against infectious diseases.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128255"},"PeriodicalIF":4.5,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring regional variations in the provision of influenza vaccination in Italy","authors":"Fabio Contarino ,&nbsp;Claudio Fiorilla ,&nbsp;Francesca Bella ,&nbsp;Andrea Orsi ,&nbsp;Antonio Mistretta ,&nbsp;Giancarlo Icardi","doi":"10.1016/j.vaccine.2026.128266","DOIUrl":"10.1016/j.vaccine.2026.128266","url":null,"abstract":"<div><h3>Background</h3><div>Influenza remains a major global public health concern, particularly affecting high-risk populations and straining healthcare systems. Vaccination coverage in Italy remains suboptimal, with wide regional variability. This study explores regional differences in the provision of influenza vaccination in Italy's decentralized health system, based on official regional circulars and institutional documents.</div></div><div><h3>Materials and methods</h3><div>Information on the vaccination campaigns was collected from official regional circulars and institutional documents, obtained via institutional websites or direct contact with regional Prevention Departments. A structured grid guided the extraction and comparison of key elements, including vaccine types, prioritized risk groups, additional coverage indicators, and procurement volumes. Vaccination coverage data were used for contextual and comparative purposes.</div></div><div><h3>Results</h3><div>Marked regional heterogeneity was observed in vaccine procurement and campaign planning. Ten regions procured all five authorized influenza vaccine types, while others omitted one or more. Several regions introduced additional coverage targets and prioritized specific high-risk populations. Reported procurement volumes varied widely, with an almost twofold difference between the regions at the extremes.</div></div><div><h3>Conclusions</h3><div>This study highlights substantial regional heterogeneity in the implementation of the 2024/2025 influenza vaccination campaign in Italy, particularly in vaccine selection, prioritization strategies, and coverage targets. Regions with clearly defined temporal priorities and additional objectives tended to achieve higher vaccination coverage. Despite differences, common structural elements, such as the central role of Prevention Departments and involvement of general practitioners, were observed. Findings underscore the need for harmonized yet context-sensitive immunization policies in decentralized healthcare systems.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128266"},"PeriodicalIF":4.5,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials","authors":"Joanne M. Langley ,&nbsp;Manish Sadarangani ,&nbsp;Christian Ockenhouse ,&nbsp;Luis Barreto ,&nbsp;Lingyun Ye ,&nbsp;Yuxiao Tang ,&nbsp;Janis L. Breeze ,&nbsp;Jodi Feser ,&nbsp;Nancy A. Hosken ,&nbsp;Indah Andi-Lolo ,&nbsp;Sybil A. Tasker ,&nbsp;Scott A. Halperin ,&nbsp;the Canadian Immunization Research Network","doi":"10.1016/j.vaccine.2026.128236","DOIUrl":"10.1016/j.vaccine.2026.128236","url":null,"abstract":"<div><h3>Background</h3><div>Pneumococcus causes substantial morbidity and mortality worldwide in children under 5. IVT PCV-25 is a 25-valent pneumococcal conjugate vaccine (PCV25) designed to prevent invasive pneumococcal disease from the serotypes predominant in children, particularly in low and middle income countries (LMICs).</div></div><div><h3>Methods</h3><div>We completed 2 randomised, parallel-group, double-blind clinical trials in Canada to evaluate the safety and immunogenicity of a single IM dose of PCV25 in healthy adults who had no history of pneumococcal vaccination or microbiologically confirmed IPD. PCV20 (Prevnar 20) was the control. In CVIA 096, 30 participants per group were randomised to PCV25 at a dose similar to PCV 20 (2.2 μg for each serotype polysaccharide (except 4.4 μg for serotype 6B) with 125 μg aluminium as aluminium phosphate (2.2/125)) or PCV20. Potentially more immunogenic formulations with higher polysaccharide and/or aluminium phosphate dose were evaluated in CVIA105, where 40 participants were randomised to PCV25 (2.2/125), 60 to PCV25 (2.2/250), 80 to PCV25 (4.4/250), and 40 to PCV20.</div></div><div><h3>Results</h3><div>Most participants were female and white. All participants were included in the safety analyses. One participant in CVIA 096 and 6 participants in CVIA 105 were excluded from the immunogenicity analyses because of protocol deviations that might interfere with immune response. Solicited and unsolicited AE profiles were similar for PCV25 and PCV20. No Grade 4 events were reported. At the highest dose, PCV25 elicited IgG and OPA responses with GMFRs of ≥2 for all 25 serotypes and for serotype 6A except for OPA response to 35B.</div></div><div><h3>Conclusions</h3><div>Multiple formulations of IVT PCV-25, a vaccine designed to cover pneumococcal serotypes prevalent in LMICs, were well tolerated and immunogenic in healthy adults. As adult immunogenicity is not fully predictive for infants, further development will evaluate safety and immunogenicity in the target infant population.</div><div><span><span><em>ClinicalTrials.gov</em></span><svg><path></path></svg></span> <span><span><em>NCT05540028</em></span><svg><path></path></svg></span><em>,</em> <span><span><em>NCT06077656</em></span><svg><path></path></svg></span></div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128236"},"PeriodicalIF":4.5,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to “A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults” [Vaccine 74 (2026) 128195]","authors":"Helen Lister ,&nbsp;Katherine Farquharson ,&nbsp;Holly Seale ,&nbsp;Louise E. Smith ,&nbsp;Tiziano Poletti ,&nbsp;Femy Amin ,&nbsp;G. James Rubin","doi":"10.1016/j.vaccine.2026.128252","DOIUrl":"10.1016/j.vaccine.2026.128252","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"75 ","pages":"Article 128252"},"PeriodicalIF":4.5,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}